IMVT
Immunovant, Inc.$22.82-0.85 (-3.59%)Prev Close$23.65·MCap$5.29B·P/E—·Vol687.9K·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
24
$2.87M
◆
Net Activity
Net Seller
$2.87M
●
Active Insiders
8
last 12 mo
Over the past 12 months, insider activity at Immunovant, Inc. (IMVT) has been exclusively selling, with 0 insider purchases totaling $0.00 and 24 insider sales totaling $2.87M. The most recent insider transaction was by Van Tuyl Christopher (officer: Chief Legal Officer), who sold $71.8K worth of shares on Mar 20, 2026. Immunovant, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $5.29B.
IMVT Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 20, 2026 | Van Tuyl Christopher | officer: Chief Legal Officer | Sell | 2,877 | $24.97 | $71.8K | 147,053 |
| Feb 27, 2026 | Gloria Melanie | officer: Chief Operating Officer | Sell | 3,238 | $27.85 | $90.2K | 172,074 |
| Jan 21, 2026 | Stout Jay S | Chief Technology Officer | Sell | 1,977 | $26.03 | $51.5K | 0 |
| Jan 7, 2026 | Stout Jay S | Chief Technology Officer | Sell | 1,203 | $26.53 | $31.9K | 0 |
| Dec 18, 2025 | Van Tuyl Christopher | Chief Legal Officer | Sell | 10,813 | $26.91 | $290.9K | 0 |
| Dec 1, 2025 | Fromkin Andrew J. | Director | Sell | 22,249 | $23.25 | $517.2K | 0 |
| Dec 1, 2025 | Hughes Douglas J. | Director | Sell | 15,000 | $23.24 | $348.7K | 0 |
| Nov 20, 2025 | Gloria Melanie | Chief Operating Officer | Sell | 12,626 | $23.62 | $298.2K | 0 |
| Oct 22, 2025 | Geffner Michael | Chief Medical Officer | Sell | 2,595 | $19.03 | $49.4K | 0 |
| Oct 22, 2025 | Stout Jay S | Chief Technology Officer | Sell | 2,520 | $19.03 | $48.0K | 0 |
| Oct 8, 2025 | Geffner Michael | Chief Medical Officer | Sell | 1,272 | $16.30 | $20.7K | 0 |
| Oct 8, 2025 | Stout Jay S | Chief Technology Officer | Sell | 1,585 | $16.30 | $25.8K | 0 |
| Jul 23, 2025 | Geffner Michael | Chief Medical Officer | Sell | 2,385 | $18.15 | $43.3K | 0 |
| Jul 23, 2025 | Stout Jay S | Chief Technology Officer | Sell | 2,805 | $18.15 | $50.9K | 0 |
| Jul 9, 2025 | Geffner Michael | Chief Medical Officer | Sell | 1,160 | $17.24 | $20.0K | 0 |
| Jul 9, 2025 | Stout Jay S | Chief Technology Officer | Sell | 1,519 | $17.24 | $26.2K | 0 |
| Apr 23, 2025 | Geffner Michael | Chief Medical Officer | Sell | 2,349 | $14.79 | $34.7K | 0 |
| Apr 23, 2025 | Stout Jay S | Chief Technology Officer | Sell | 1,925 | $14.79 | $28.5K | 0 |
| Apr 16, 2025 | Barnett Eva Renee | Chief Financial Officer | Sell | 2,993 | $14.89 | $44.6K | 0 |
| Apr 16, 2025 | Salzmann Peter | Chief Executive Officer | Sell | 8,321 | $14.89 | $123.9K | 0 |
| Apr 9, 2025 | Barnett Eva Renee | Chief Financial Officer | Sell | 11,063 | $12.99 | $143.7K | 0 |
| Apr 9, 2025 | Geffner Michael | Chief Medical Officer | Sell | 6,169 | $12.99 | $80.1K | 0 |
| Apr 9, 2025 | Salzmann Peter | Chief Executive Officer | Sell | 28,094 | $12.99 | $364.9K | 0 |
| Apr 9, 2025 | Stout Jay S | Chief Technology Officer | Sell | 5,004 | $12.99 | $65.0K | 0 |
| Mar 7, 2025 | Fromkin Andrew J. | Director | Sell | 8,000 | $19.60 | $156.8K | 0 |
| Feb 21, 2025 | Barnett Eva Renee | Chief Financial Officer | Sell | 2,814 | $20.86 | $58.7K | 321,952 |
| Feb 21, 2025 | Macias William L. | Chief Medical Officer | Sell | 2,055 | $20.86 | $42.9K | 357,353 |
| Feb 21, 2025 | Salzmann Peter | Chief Executive Officer | Sell | 15,439 | $20.86 | $322.1K | 948,786 |
| Jan 24, 2025 | Geffner Michael | Chief Medical Officer | Sell | 2,657 | $23.59 | $62.7K | 132,314 |
| Jan 24, 2025 | Stout Jay S | Chief Technology Officer | Sell | 2,195 | $23.59 | $51.8K | 139,991 |
| Jan 17, 2025 | Barnett Eva Renee | Chief Financial Officer | Sell | 2,298 | $23.83 | $54.8K | 324,875 |
| Jan 17, 2025 | Macias William L. | Chief Medical Officer | Sell | 2,383 | $23.83 | $56.8K | 359,908 |
| Jan 17, 2025 | Salzmann Peter | Chief Executive Officer | Sell | 8,767 | $23.83 | $208.9K | 964,640 |
| Jan 15, 2025 | Roivant Sciences Ltd. | Buy | 16,845,010 | $20.00 | $336.90M | 96,650,344 | |
| Jan 10, 2025 | Barnett Eva Renee | Chief Financial Officer | Sell | 4,105 | $24.10 | $98.9K | 327,064 |
| Jan 10, 2025 | Salzmann Peter | Chief Executive Officer | Sell | 5,105 | $24.10 | $123.0K | 972,992 |
| Dec 4, 2024 | Hughes Douglas J. | Director | Sell | 5,425 | $28.54 | $154.8K | 119,585 |
| Dec 4, 2024 | Pande Atul | Director | Sell | 7,750 | $28.54 | $221.2K | 86,663 |
| Nov 22, 2024 | Barnett Eva Renee | Chief Financial Officer | Sell | 4,174 | $25.45 | $106.2K | 331,169 |
| Nov 22, 2024 | Levine Mark S. | Chief Legal Officer | Sell | 3,650 | $25.45 | $92.9K | 319,228 |
| Nov 22, 2024 | Macias William L. | Chief Medical Officer | Sell | 3,353 | $25.45 | $85.3K | 361,791 |
| Nov 22, 2024 | Salzmann Peter | Chief Executive Officer | Sell | 16,692 | $25.45 | $424.8K | 978,097 |
| Oct 25, 2024 | Geffner Michael | Chief Medical Officer | Sell | 3,189 | $29.53 | $94.2K | 134,971 |
| Oct 25, 2024 | Levine Mark S. | Chief Legal Officer | Sell | 4,361 | $29.53 | $128.8K | 322,878 |
| Oct 25, 2024 | Stout Jay S | Chief Technology Officer | Sell | 2,740 | $29.53 | $80.9K | 142,186 |
| Oct 18, 2024 | Barnett Eva Renee | Chief Financial Officer | Sell | 3,271 | $28.79 | $94.2K | 335,343 |
| Oct 18, 2024 | Levine Mark S. | Chief Legal Officer | Sell | 2,860 | $28.79 | $82.3K | 327,239 |
| Oct 18, 2024 | Macias William L. | Chief Medical Officer | Sell | 3,188 | $28.79 | $91.8K | 365,705 |
| Oct 18, 2024 | Salzmann Peter | Chief Executive Officer | Sell | 9,095 | $28.79 | $261.8K | 994,789 |
| Oct 11, 2024 | Barnett Eva Renee | Chief Financial Officer | Sell | 5,162 | $29.56 | $152.6K | 338,614 |
Showing 1–50 of 162
1 / 4
IMVT Insider Buying Activity
The following table shows recent insider purchases of Immunovant, Inc. (IMVT) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jan 15, 2025 | Roivant Sciences Ltd. | Buy | 16,845,010 | $20.00 | $336.90M | 96,650,344 |
IMVT Insider Selling Activity
The following table shows recent insider sales of Immunovant, Inc. (IMVT) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 20, 2026 | Van Tuyl Christopher | officer: Chief Legal Officer | Sell | 2,877 | $24.97 | $71.8K | 147,053 |
| Feb 27, 2026 | Gloria Melanie | officer: Chief Operating Officer | Sell | 3,238 | $27.85 | $90.2K | 172,074 |
| Jan 21, 2026 | Stout Jay S | Chief Technology Officer | Sell | 1,977 | $26.03 | $51.5K | 0 |
| Jan 7, 2026 | Stout Jay S | Chief Technology Officer | Sell | 1,203 | $26.53 | $31.9K | 0 |
| Dec 18, 2025 | Van Tuyl Christopher | Chief Legal Officer | Sell | 10,813 | $26.91 | $290.9K | 0 |
| Dec 1, 2025 | Fromkin Andrew J. | Director | Sell | 22,249 | $23.25 | $517.2K | 0 |
| Dec 1, 2025 | Hughes Douglas J. | Director | Sell | 15,000 | $23.24 | $348.7K | 0 |
| Nov 20, 2025 | Gloria Melanie | Chief Operating Officer | Sell | 12,626 | $23.62 | $298.2K | 0 |
| Oct 22, 2025 | Geffner Michael | Chief Medical Officer | Sell | 2,595 | $19.03 | $49.4K | 0 |
| Oct 22, 2025 | Stout Jay S | Chief Technology Officer | Sell | 2,520 | $19.03 | $48.0K | 0 |
| Oct 8, 2025 | Geffner Michael | Chief Medical Officer | Sell | 1,272 | $16.30 | $20.7K | 0 |
| Oct 8, 2025 | Stout Jay S | Chief Technology Officer | Sell | 1,585 | $16.30 | $25.8K | 0 |
| Jul 23, 2025 | Geffner Michael | Chief Medical Officer | Sell | 2,385 | $18.15 | $43.3K | 0 |
| Jul 23, 2025 | Stout Jay S | Chief Technology Officer | Sell | 2,805 | $18.15 | $50.9K | 0 |
| Jul 9, 2025 | Geffner Michael | Chief Medical Officer | Sell | 1,160 | $17.24 | $20.0K | 0 |
| Jul 9, 2025 | Stout Jay S | Chief Technology Officer | Sell | 1,519 | $17.24 | $26.2K | 0 |
| Apr 23, 2025 | Geffner Michael | Chief Medical Officer | Sell | 2,349 | $14.79 | $34.7K | 0 |
| Apr 23, 2025 | Stout Jay S | Chief Technology Officer | Sell | 1,925 | $14.79 | $28.5K | 0 |
| Apr 16, 2025 | Barnett Eva Renee | Chief Financial Officer | Sell | 2,993 | $14.89 | $44.6K | 0 |
| Apr 16, 2025 | Salzmann Peter | Chief Executive Officer | Sell | 8,321 | $14.89 | $123.9K | 0 |
| Apr 9, 2025 | Barnett Eva Renee | Chief Financial Officer | Sell | 11,063 | $12.99 | $143.7K | 0 |
| Apr 9, 2025 | Geffner Michael | Chief Medical Officer | Sell | 6,169 | $12.99 | $80.1K | 0 |
| Apr 9, 2025 | Salzmann Peter | Chief Executive Officer | Sell | 28,094 | $12.99 | $364.9K | 0 |
| Apr 9, 2025 | Stout Jay S | Chief Technology Officer | Sell | 5,004 | $12.99 | $65.0K | 0 |
| Mar 7, 2025 | Fromkin Andrew J. | Director | Sell | 8,000 | $19.60 | $156.8K | 0 |
| Feb 21, 2025 | Barnett Eva Renee | Chief Financial Officer | Sell | 2,814 | $20.86 | $58.7K | 321,952 |
| Feb 21, 2025 | Macias William L. | Chief Medical Officer | Sell | 2,055 | $20.86 | $42.9K | 357,353 |
| Feb 21, 2025 | Salzmann Peter | Chief Executive Officer | Sell | 15,439 | $20.86 | $322.1K | 948,786 |
| Jan 24, 2025 | Geffner Michael | Chief Medical Officer | Sell | 2,657 | $23.59 | $62.7K | 132,314 |
| Jan 24, 2025 | Stout Jay S | Chief Technology Officer | Sell | 2,195 | $23.59 | $51.8K | 139,991 |
| Jan 17, 2025 | Barnett Eva Renee | Chief Financial Officer | Sell | 2,298 | $23.83 | $54.8K | 324,875 |
| Jan 17, 2025 | Macias William L. | Chief Medical Officer | Sell | 2,383 | $23.83 | $56.8K | 359,908 |
| Jan 17, 2025 | Salzmann Peter | Chief Executive Officer | Sell | 8,767 | $23.83 | $208.9K | 964,640 |
| Jan 10, 2025 | Barnett Eva Renee | Chief Financial Officer | Sell | 4,105 | $24.10 | $98.9K | 327,064 |
| Jan 10, 2025 | Salzmann Peter | Chief Executive Officer | Sell | 5,105 | $24.10 | $123.0K | 972,992 |
| Dec 4, 2024 | Hughes Douglas J. | Director | Sell | 5,425 | $28.54 | $154.8K | 119,585 |
| Dec 4, 2024 | Pande Atul | Director | Sell | 7,750 | $28.54 | $221.2K | 86,663 |
| Nov 22, 2024 | Barnett Eva Renee | Chief Financial Officer | Sell | 4,174 | $25.45 | $106.2K | 331,169 |
| Nov 22, 2024 | Levine Mark S. | Chief Legal Officer | Sell | 3,650 | $25.45 | $92.9K | 319,228 |
| Nov 22, 2024 | Macias William L. | Chief Medical Officer | Sell | 3,353 | $25.45 | $85.3K | 361,791 |
| Nov 22, 2024 | Salzmann Peter | Chief Executive Officer | Sell | 16,692 | $25.45 | $424.8K | 978,097 |
| Oct 25, 2024 | Geffner Michael | Chief Medical Officer | Sell | 3,189 | $29.53 | $94.2K | 134,971 |
| Oct 25, 2024 | Levine Mark S. | Chief Legal Officer | Sell | 4,361 | $29.53 | $128.8K | 322,878 |
| Oct 25, 2024 | Stout Jay S | Chief Technology Officer | Sell | 2,740 | $29.53 | $80.9K | 142,186 |
| Oct 18, 2024 | Barnett Eva Renee | Chief Financial Officer | Sell | 3,271 | $28.79 | $94.2K | 335,343 |
| Oct 18, 2024 | Levine Mark S. | Chief Legal Officer | Sell | 2,860 | $28.79 | $82.3K | 327,239 |
| Oct 18, 2024 | Macias William L. | Chief Medical Officer | Sell | 3,188 | $28.79 | $91.8K | 365,705 |
| Oct 18, 2024 | Salzmann Peter | Chief Executive Officer | Sell | 9,095 | $28.79 | $261.8K | 994,789 |
| Oct 11, 2024 | Barnett Eva Renee | Chief Financial Officer | Sell | 5,162 | $29.56 | $152.6K | 338,614 |
IMVT Insiders
Similar Stocks to IMVT
VRTX
Vertex Pharmaceuticals Incorporated
$454.00-0.96%
$115.32B
REGN
Regeneron Pharmaceuticals, Inc.
$732.87-0.89%
$76.15B
ALNY
Alnylam Pharmaceuticals, Inc.
$312.17+0.99%
$41.40B
INSM
Insmed Incorporated
$136.00-4.42%
$29.32B
UTHR
United Therapeutics Corporation
$524.28-0.61%
$23.50B
MRNA
Moderna, Inc.
$50.80-3.04%
$20.76B
ROIV
Roivant Sciences Ltd.
$27.22-2.16%
$20.08B
RPRX
Royalty Pharma plc
$45.37-0.35%
$19.56B